FDA Warns Singapore Drugmaker Over Validation, Labeling Issues

Drug Industry Daily
A A
The FDA hit drugmaker Opto-Pharm with a warning letter, citing a lack of written procedures for preventing contamination of sterile drug products, as well as problems with validation, testing and labeling.

To View This Article:

Login

Subscribe To Drug Industry Daily